Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MOH Appoints Fuwai Hospital As Quality Control Center On Cardiovascular Disease

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health has appointed the China Medical Science Academy's Fuwai Hospital as its quality control center on cardiovascular disease from June 1, 2009 through June 1, 2012. The hospital will conduct national quality control tasks of intervention treatment for congenital heart diseases and arrhythmia. The MOH will require Fuwai Hospital to collate, conduct statistical analysis and assess treatment cases reported by all localities, release half-yearly quality control reports and send feedback to medical care institutions. To be a qualified quality control center, it will add the necessary professionals and facilities, improve relevant rules and quality control structure, and map out workflow procedures. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel